144 Results for "

lymphocytic leukemia

" in MedChemExpress (MCE) Product Catalog:
Products (144)

144 Results for "lymphocytic leukemia" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-17600
CAS No.: 1420477-60-6
Synonyms: Calquence; ACP-196
Target:  

Btk

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13024
CAS No.: 1020172-07-9
Purity:  99.91%
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13599
CAS No.: 4291-63-8
Purity:  99.97%
Synonyms: 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B1640
CAS No.: 58-54-8
Synonyms: Etacrynic acid
Ethacrynic acid has anti-inflammatory and anticancer activity. Ethacrynic acid is an orally active diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferase (GSTs) and Wnt signaling pathways. Ethacrynic acid is a radiosensitizer. Ethacrynic acid can inhibit airway smooth muscle (ASM) contraction in mice. Ethacrynic acid can increase the outflow of aqueous humor from the eye for the study of glaucoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14951
CAS No.: 402567-16-2
Purity:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Research Areas:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-12279
CAS No.: 1532533-67-7
Purity:  98.94%
Synonyms: TGR-1202; RP5264
Target:  

PI3K Casein Kinase

Research Areas:  

Cancer

Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15322
CAS No.: 1370261-96-3
Purity:  99.38%
Synonyms: P505-15; PRT-2607; BIIB-057
Target:  

Syk Apoptosis Caspase

Research Areas:  

Inflammation/Immunology Cancer

PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-122562
CAS No.: 2231744-29-7
Purity:  98.35%
Target:  

PROTACs Btk

Research Areas:  

Cancer

MT-802 is a BTK PROTAC degrader. MT-802 degrades wild-type BTK (DC50 = 14.6 nM) and BTK mutants including E41K, C481S (DC50 = 14.9 nM), C481R, C481Y, C481T, C481F, L528W, and inhibits their Y223 phosphorylation. BI-4732 can be used for the study of Ibrutinib (HY-10997)-resistant chronic lymphocytic leukemia (CLL). (Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-141371), E3 ligase ligand-linker conjugate (HY-176340)) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-12279C
CAS No.: 1532533-78-0
Purity:  99.04%
Synonyms: TGR-1202 hydrochloride; RP5264 hydrochloride
Target:  

PI3K Casein Kinase

Research Areas:  

Cancer

Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12974
CAS No.: 1194961-19-7
Purity:  98.98%
Synonyms: PRT318
Target:  

Syk Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13593
CAS No.: 305-03-3
Purity:  98.76%
Synonyms: CB-1348; WR-139013
Research Areas:  

Neurological Disease Cancer

Chlorambucil (CB-1348), an orally active antineoplastic agent, is a CNS-penetrant bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12974A
CAS No.: 3032567-93-1
Synonyms: PRT318 dihydrochloride
Target:  

Syk Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-129390
CAS No.: 1655504-04-3
Purity:  99.97%
Synonyms: ICP-022
Target:  

Btk

Research Areas:  

Cancer

Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114989
CAS No.: 1362243-70-6
Purity:  99.77%
Target:  

Apoptosis

Research Areas:  

Cancer

Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N6065
CAS No.: 73069-27-9
Synonyms: (+)-Praeruptorin A
Praeruptorin A ((+)-Praeruptorin A) is an orally active isomer of (±)-Praeruptorin A (HY-N0081). Praeruptorin A also acts as a Calcium channel blocker. Praeruptorin A can be isolated from Peucedanum. Praeruptorin A serves as a substrate for CYP3A4. Praeruptorin A downregulates NMDA receptors containing GluN2B and inhibits neuronal Apoptosis. Praeruptorin A mediates vasodilation, inhibits vascular hypertrophy and reduces blood pressure. Praeruptorin A can be used in research related to neurological diseases, myocardial ischemia, heart failure, exertional angina, renovascular hypertension and spontaneous hypertension .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N6727
CAS No.: 67-99-2
Synonyms: Aspergillin
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-129179
CAS No.: 2180923-05-9
Purity:  99.28%
Synonyms: APG-2575; Bcl-2/Bcl-xl inhibitor 1
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-160041
CAS No.: 1390628-22-4
Synonyms: NOX-A12
Target:  

CXCR

Research Areas:  

Cancer

Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-160041A
Synonyms: NOX-A12 sodium
Target:  

CXCR

Research Areas:  

Cancer

Olaptesed pegol (NOX-A12) sodium is a pegylated L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99272
CAS No.: 1375830-34-4
Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Target:  

CXCR

Research Areas:  

Cancer

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
loading...
    loading...